02142 and 6XY Related Headlines
Go Back- Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C
- Harbour BioMed wins $20.2 million patent case against Amgen
- Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
- Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
- Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
- Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
- Harbour BioMed partner begins COPD trial of HBM9378/WIN378 antibody
- First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
- Harbour BioMed reports preclinical data for obesity drug candidate LET003
- Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
- Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
- Harbour BioMed appoints Dr. Adam Zong as president
- Harbour BioMed Appoints Dr. Adam Zong as President
- Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
- Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
- Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
- Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
- Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
- Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- Harbour BioMed partners with Bristol Myers Squibb on antibody development
- Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
- Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
- Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
- Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
- Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
- Harbour BioMed Reports 2025 Interim Results
- Harbour BioMed names Yajie Li as chief medical officer
- Harbour BioMed names Yajie Li as chief medical officer
- Harbour BioMed Appoints Yajie Li as Chief Medical Officer
- Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
- Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
- Harbour BioMed partner starts phase 2 asthma drug trial
- HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
- Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
02142 and 6XY Related Press Releases
Go Back- Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C
- Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
- Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
- Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
- Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
- First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
- Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
- Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
- Harbour BioMed Appoints Dr. Adam Zong as President
- Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
- Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
- Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
- Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
- Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
- Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
- Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
- Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
- Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
- Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
- Harbour BioMed Reports 2025 Interim Results
- Harbour BioMed Appoints Yajie Li as Chief Medical Officer
- Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
- Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
- HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
- Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
